Inventiva (NASDAQ:IVA) Stock Jumps 5.5% – Here’s Why

Inventiva S.A. Sponsored ADR (NASDAQ:IVA)’s stock price traded up 5.5% during mid-day trading on Monday. The company traded as high as $3.56 and last traded at $3.5540. 1,594,845 shares changed hands during trading, an increase of 108% from the average daily volume of 767,526 shares. The stock had previously closed at $3.37.

Trending Headlines about Inventiva

Here are the key news stories impacting Inventiva this week:

• Positive Sentiment: Inventiva reported that its second-quarter performance exceeded expectations, while its unaudited first-half 2026 net loss narrowed from the prior-year period. The improvement may ease near-term concerns about operating expenses and cash consumption. Inventiva S.A. Reports Earnings Results for the Half Year Ended June 30, 2026
• Positive Sentiment: The company expects a clinical readout for its MASH drug lanifibranor later this quarter. Positive data could represent a significant catalyst because the program is central to Inventiva’s growth prospects and investor valuation. Inventiva H1 Loss Plunges; MASH Drug Readout Expected This Quarter
• Neutral Sentiment: Inventiva said its cash runway remains unchanged through the end of the second quarter of 2027, providing additional time to reach important clinical milestones without an immediate funding requirement indicated in the update. Inventiva Cash Runway Update
• Negative Sentiment: Despite the improved loss, Inventiva remains an early-stage biotechnology company with limited revenue and continuing cash needs. Investors are therefore treating the earnings improvement as secondary to the upcoming lanifibranor data, making the stock vulnerable if the readout disappoints or is delayed. Inventiva Reports Unaudited 2026 First-Half Financial Results

Analyst Ratings Changes

A number of research firms have commented on IVA. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Inventiva in a research report on Friday, July 17th. Piper Sandler reiterated an “overweight” rating on shares of Inventiva in a research report on Wednesday, September 16th. Guggenheim boosted their price target on shares of Inventiva from $11.00 to $14.00 and gave the company a “buy” rating in a research note on Tuesday, September 15th. Finally, Cantor Fitzgerald began coverage on shares of Inventiva in a report on Friday, July 17th. They issued an “overweight” rating on the stock. Three investment analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Inventiva currently has a consensus rating of “Buy” and an average price target of $15.75.

Inventiva Stock Performance

The business has a 50-day moving average price of $4.42 and a two-hundred day moving average price of $4.75.

Inventiva (NASDAQ:IVA) last released its earnings results on Friday, August 14th. The company reported ($0.14) earnings per share (EPS) for the quarter. The company had revenue of $0.75 million during the quarter. As a group, research analysts forecast that Inventiva S.A. Sponsored ADR will post -0.85 EPS for the current fiscal year.

Hedge Funds Weigh In On Inventiva

Several hedge funds and other institutional investors have recently made changes to their positions in IVA. Engineers Gate Manager LP grew its position in shares of Inventiva by 155.5% during the second quarter. Engineers Gate Manager LP now owns 71,116 shares of the company’s stock worth $269,000 after buying an additional 43,280 shares in the last quarter. Persistent Asset Partners Ltd acquired a new stake in Inventiva in the fourth quarter valued at approximately $603,000. Seven Fleet Capital Management LP acquired a new stake in Inventiva in the first quarter valued at approximately $1,111,000. Eventide Asset Management LLC purchased a new position in Inventiva in the fourth quarter worth approximately $1,155,000. Finally, Propel Bio Management LLC purchased a new position in Inventiva in the fourth quarter worth approximately $4,650,000. Hedge funds and other institutional investors own 19.06% of the company’s stock.

Inventiva Company Profile

Inventiva SA is a clinical-stage biopharmaceutical company headquartered in Daix, France. The company develops small-molecule therapies for metabolic, liver and autoimmune diseases, with a focus on conditions that have limited treatment options.

Inventiva’s lead product candidate is lanifibranor, an oral pan-PPAR agonist being developed for metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH). The investigational therapy is intended to address liver inflammation and fibrosis associated with the disease and is being evaluated in late-stage clinical development.